東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Linked to FindBook

Google Book

Amazon

博客來

Evaluating the Potential of Pentoxifylline as a Hypoxia Modifier in Head and Neck Cancer.

Record Type:	Electronic resources : Monograph/item
Title/Author:	Evaluating the Potential of Pentoxifylline as a Hypoxia Modifier in Head and Neck Cancer./
Author:	Alshammary , Amirah .
Published:	Ann Arbor : ProQuest Dissertations & Theses, : 2020,
Description:	47 p.
Notes:	Source: Masters Abstracts International, Volume: 82-05.
Contained By:	Masters Abstracts International82-05.
Subject:	Oncology. -
Online resource:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=28090708
ISBN:	9798678123749

Evaluating the Potential of Pentoxifylline as a Hypoxia Modifier in Head and Neck Cancer.
Alshammary , Amirah .

Evaluating the Potential of Pentoxifylline as a Hypoxia Modifier in Head and Neck Cancer. - Ann Arbor : ProQuest Dissertations & Theses, 2020 - 47 p.

Source: Masters Abstracts International, Volume: 82-05.

Thesis (M.S.)--State University of New York at Buffalo, 2020.

This item must not be sold to any third party vendors.

Purpose: Hypoxia is a major source of resistance to radiation therapy (RT) in most solid tumors including head and neck squamous cell carcinoma (HNSCC). As a result, there is an active interest in identifying agents that can alleviate hypoxia and sensitize tumors to RT. Pentoxifylline (PTX) is a clinically approved agent known to increase red blood cell deformability and improve blood flow. To date, there is limited in vivo evidence on the effects of PTX on tumor vascularity and hypoxia. In this work, we examined the activity of PTX against HNSCC in vitro and monitored the effects of PTX on tumor growth and vascularity in vivo using ultrasound (US) with co-registered photoacoustic imaging (PAI).Methods: Experimental studies were conducted using orthotopic (i) human FaDu tumor xenografts established in immunodeficient mice, and (ii) murine RP-MOC1 tumors established in immunocompetent C57BL/6 mice. Tumor-bearing mice were treated with PTX 200mg/kg and acute changes in tumor vascular function were evaluated over a 24 hour period using combined US-PAI. Percent vascularity (PV) was calculated from Power doppler. Tumor oxygen saturation (%sO2 average and sO2% total) and total hemoglobin concentration (HbT) were measured using photoacoustic imaging (PAI). Body weight measurements were acquired throughout the study to assess acute toxicity.Results: PTX did not sensitize cells to RT in vitro. We noted a higher number of colonies formed in the group treated with PTX+RT compared to RT alone group. Treatment with PTX (200 mg/kg) resulted in a significant increase in PV and %sO2 1hour post injection in FaDu tumors. In comparison, a transient increase in HbT average at 15 minutes post PTX injection (dose?) in RP-MOC1 tumor model. Conclusion: US-PAI detected transient improvement in tumor perfusion in HNSCC following PTX treatment. The observed effects were time- and tumor-dependent. Further investigation into the biological effects of PTX alone and in combination with RT against HNSCC is warranted.

ISBN: 9798678123749Subjects--Topical Terms:

751006
Oncology.
Subjects--Index Terms:

Head and Neck cancer

Evaluating the Potential of Pentoxifylline as a Hypoxia Modifier in Head and Neck Cancer.
LDR:03174nmm a2200373 4500 001 2347046
005 20220711065233.5
008 241004s2020 ||||||||||||||||| ||eng d
020 $a 9798678123749
035 $a (MiAaPQ)AAI28090708
035 $a AAI28090708
040 $a MiAaPQ $c MiAaPQ
100 1 $a Alshammary , Amirah . $3 3686256
245 1 0 $a Evaluating the Potential of Pentoxifylline as a Hypoxia Modifier in Head and Neck Cancer.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2020
300 $a 47 p.
500 $a Source: Masters Abstracts International, Volume: 82-05.
500 $a Advisor: Seshadri, Mukund.
502 $a Thesis (M.S.)--State University of New York at Buffalo, 2020.
506 $a This item must not be sold to any third party vendors.
520 $a Purpose: Hypoxia is a major source of resistance to radiation therapy (RT) in most solid tumors including head and neck squamous cell carcinoma (HNSCC). As a result, there is an active interest in identifying agents that can alleviate hypoxia and sensitize tumors to RT. Pentoxifylline (PTX) is a clinically approved agent known to increase red blood cell deformability and improve blood flow. To date, there is limited in vivo evidence on the effects of PTX on tumor vascularity and hypoxia. In this work, we examined the activity of PTX against HNSCC in vitro and monitored the effects of PTX on tumor growth and vascularity in vivo using ultrasound (US) with co-registered photoacoustic imaging (PAI).Methods: Experimental studies were conducted using orthotopic (i) human FaDu tumor xenografts established in immunodeficient mice, and (ii) murine RP-MOC1 tumors established in immunocompetent C57BL/6 mice. Tumor-bearing mice were treated with PTX 200mg/kg and acute changes in tumor vascular function were evaluated over a 24 hour period using combined US-PAI. Percent vascularity (PV) was calculated from Power doppler. Tumor oxygen saturation (%sO2 average and sO2% total) and total hemoglobin concentration (HbT) were measured using photoacoustic imaging (PAI). Body weight measurements were acquired throughout the study to assess acute toxicity.Results: PTX did not sensitize cells to RT in vitro. We noted a higher number of colonies formed in the group treated with PTX+RT compared to RT alone group. Treatment with PTX (200 mg/kg) resulted in a significant increase in PV and %sO2 1hour post injection in FaDu tumors. In comparison, a transient increase in HbT average at 15 minutes post PTX injection (dose?) in RP-MOC1 tumor model. Conclusion: US-PAI detected transient improvement in tumor perfusion in HNSCC following PTX treatment. The observed effects were time- and tumor-dependent. Further investigation into the biological effects of PTX alone and in combination with RT against HNSCC is warranted.
590 $a School code: 0656.
650 4 $a Oncology. $3 751006
650 4 $a Pharmacology. $3 634543
650 4 $a Medical imaging. $3 3172799
650 4 $a Biophysics. $3 518360
653 $a Head and Neck cancer
653 $a Hypoxia
653 $a Pentoxifylline
653 $a Photoacoustic imaging
690 $a 0992
690 $a 0786
690 $a 0574
690 $a 0419
710 2 $a State University of New York at Buffalo. $b Roswell Park . Cancer Sciences. $3 3685157
773 0 $t Masters Abstracts International $g 82-05.
790 $a 0656
791 $a M.S.
792 $a 2020
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=28090708